C avernous malformations are clusters of endothelium-lined sinusoidal channels filled with blood at various stages of evolution. 25, 26, 30, 35 These channels, lacking a reinforcing elastin or smooth muscle layer, are directly apposed without intervening neural parenchyma.
database search using the terms "cavernoma," "cavernous malformation," "natural history," "bleeding," and "hemorrhage" was performed from January 1, 1985, through October 17, 2015 . We incorporated English-language studies that provided annual hemorrhage rates for CMs, defined as the ratio of total number of hemorrhages to total number of patient-years of follow-up. Eligibility assessment was performed independently by both reviewers. Studies that did not provide the information to allow an annual hemorrhage rate to be calculated were excluded. In cases of multiple studies from the same patient population, the most recent one providing overall annual hemorrhage rates and risk factors for hemorrhage was used. For our calculations of demographic factors and overall annual hemorrhage rates, we included only studies evaluating a full cohort of patients with cerebral CMs-those studying only subgroups of patients (e.g., pediatric series, brainstem series) were excluded. For our evaluation of hemorrhage risk factors, we initially compiled results across studies that evaluated risk factors via the log-rank test, logistic regression, or Cox regression. Hazard ratios were pooled across studies that provided them.
Data Extraction
Data extraction was performed independently by both authors and was consistent. We extracted epidemiological data, including patient age, sex, presentation modality, CM location, multiplicity, and the presence of associated developmental venous anomalies (DVAs). We then calculated the number of hemorrhages and patient-years of follow-up across these studies, also making note of subgroup analyses for hemorrhage risk factors. Hazard ratios were extracted for each risk factor when provided.
Statistical Analysis
Statistical analysis was performed using the rmeta package in R version 2.11. Proportions were transformed with the logit transformation, and hazard ratios were logtransformed. Both were pooled using the fixed effects and random effects models. The DerSimonian-Laird estimate was used in the random effects model. Confidence intervals were calculated using the Clopper-Pearson interval. The Cochran Q statistic was used to calculate betweenstudy heterogeneity. The assumption of homogeneity was considered invalid when p < 0.10. Results from the random effects model were used. Publication bias was assessed using Egger's test with p < 0.05 indicating significant bias.
Results
Our literature search is illustrated in Fig. 1 . After an initial screening of 1550 articles, 70 full-text articles were perused for eligibility, affording 12 overall natural history studies 2, 3, 7, 11, 14, 19, 22, 23, 29, 31, 34, 36 and 9 studies statistically evaluating risk factors for hemorrhage. 3, 4, 14, 17, 19, 23, 24, 29, 31 The majority of variables (incidental, seizure, neurological deficit, hemorrhage, brainstem, multiplicity, and hazard ratios for age, female sex, size, hemorrhage, and multiplicity) had significant between-study heterogeneity; therefore the results of the random effects model were used.
Demographics
Across 12 natural history studies with 1610 patients, the mean age at presentation was 42.7 years old and 52% of patients (95% CI 49%-55% from random effects analysis) were female (Table 1) . 2, 3, 7, 11, 14, 19, 22, 23, 29, 31, 34, 36 Across 10 natural history studies, presentation modality was seizure in 30% (95% CI 25%-35%), hemorrhage in 26% (95% CI 17%-37%), incidental in 17% (95% CI 9-31%), and focal deficits only in 16% of cases (95% CI 11%-23%). 2, 3, 7, 11, 14, 19, 29, 31, 36 Across 7 studies, CM location was lobar in 66% (95% CI 61%-70%), brainstem in 18% (95% CI 13%-24%), deep supratentorial in 8% (95% CI 6%-10%), and cerebellar in 8% (95% CI 5%-11%). 2, 3, 7, 22, 29, 31, 34 Across 9 studies, 24% of patients harbored multiple CMs (95% CI 19%-29%), 3, 7, 11, 14, 22, 23, 29, 31, 36 and across 5 studies 18% of patients had DVAs (95% CI 14%-22%). 3, 7, 14, 29, 31 There was no publication bias except for brainstem location (Egger's test p = 0.04). Table 2 summarizes overall CM hemorrhage rates in 12 studies. 2, 3, 7, 11, 14, 19, 22, 23, 29, 31, 34, 36 All broadly defined a hemorrhage as a symptomatic event with radiographic evidence of hemorrhage. In 2 studies, a CM size increase of at least 20% was considered adequate radiographic evidence for a hemorrhagic event;
Hemorrhage Rates
19,31 on the other hand, 2 other studies specifically required evidence of extralesional hemorrhage or a positive lumbar puncture to define a hemorrhagic event. 29, 34 Two studies only provided overall annual hemorrhage rates per lesion-year, and 1 study that required extralesional hemorrhage or a positive lumbar puncture in addition to a symptomatic event cited an annual rate of 0.7% per lesion-year. 34 The other study that allowed for a size increase of 20% or intralesional/extralesional hemorrhage to define an event cited an annual rate of 4.5% per lesion-year. 19 Three early studies assumed CM lesion presence since birth; 7, 11, 22 the annual hemorrhage rate across these 3 studies ranged from 0.3% to 2.3% per patient-year. Pooling results from these 3 studies, over 8265.6 patientyears of follow-up, the annual hemorrhage rate was 1.4% per patient-year (95% CI 0.8%-2.5%). Seven natural history studies that defined the observation period from presentation until last follow-up provided hemorrhage rates ranging from 0.5% to 10.0% per patient-year. 2, 3, 14, 23, 29, 31, 36 Pooling results from these studies, over 5081.2 patientyears of follow-up, the annual hemorrhage rate was 2.5% per patient-year (95% CI 1.3%-5.1%; Fig. 2A ). Table 3 summarizes results across 9 studies evaluating risk factors for CM hemorrhage using log-rank testing, logistic regression, or Cox regression. 3, 4, 14, 17, 19, 23, 24, 29, 31 Prior CM hemorrhage was a significant risk factor for hemorrhage in 6 of 7 studies. 3, 14, 17, 19, 23, 24, 31 Deep location was a significant risk factor for hemorrhage in one study 31 and neared statistical significance as a significant risk factor for hemorrhage in another. 19 In both of these studies, the definition for CM hemorrhage also included a size of increase of the lesion of at least 20%. Two other studies did not find deep location to be a significant risk factor for CM hemorrhage. 4, 29 Female sex was a significant risk factor for hemorrhage in 2 of the 9 reviewed studies; 24,29 in 1 study, however, male sex was a significant risk factor for hemorrhage.
Risk Factors for CM Hemorrhage
14 One of 4 studies cited younger age as a significant risk factor for hemorrhage. 4 An associated DVA was seen as a significant risk factor for hemorrhage in one of 5 studies. 17 Lesion multiplicity was a significant risk factor for hemorrhage in a study that evaluated hemorrhage risk in patient-years; 14 in another study that evaluated risk per lesion-year, a trend was in fact seen toward protection from hemorrhage. 17 Five other studies did not find lesion multiplicity to be a significant risk factor for hemorrhage. 3, 19, 23, 24, 31 CM size was not a significant risk factor for hemorrhage in any of the 3 studies evaluating this risk factor. 19, 24, 29 Five studies provided hazard ratios for hemorrhage risk factors (Table 4 
Discussion
Hemorrhage from cerebral CMs is the most studied aspect of their natural history. 2, 3, 7, 11, 14, 19, 22, 23, 29, 31, 34, 36 Nevertheless, there is still considerable controversy and variability in cited rates and risk factors for hemorrhage. Various study designs and hemorrhage definitions have contributed to this heterogeneity. Specifically, studies that derive their cohort of patients from an institutional review of imaging are likely to harbor more benign CMs with smaller proportions of hemorrhagic lesions. 11, 34 Owing to both the study design itself and the resultant smaller proportion of hemorrhagic lesions in the cohort, the calculated annual hemorrhage rate may be an underestimate due to selection bias. On the other hand, studies from surgical centers that evaluate a "pre-treatment" hemorrhage rate may report inflated rates due to referral bias and a high proportion of hemorrhagic CMs. 2 As a means to curtail these limitations and bias, we have pooled results across the literature. Across 3 early studies that assumed CM presence since birth, the annual hemorrhage rate was 1.4% (95% CI 0.8%-2.5%).
7,11,22 Across 7 studies that began followup at the time of clinical presentation, the annual hemorrhage rate was 2.5% (95% CI 1.3%-5.1%).
2,3,14,23,29,31,36 As expected, this approach provided a higher hemorrhage rate given the smaller amount of provided patient-years of follow-up. Generally, modern approaches to natural history have espoused this follow-up approach, which bears particular relevance for CMs given the accumulating literature suggesting that a substantial proportion of these lesions are acquired. 5, 6, 12, 18 However, overall annual hemorrhage rates bear little meaning for individualized patient management. Stratified rates based on known risk factors have far greater utility in understanding disease pathology for treatment planning and for patient counseling.
Hemorrhage Risk Factors
Nearly ubiquitously across our reviewed studies, hemorrhage was a significant risk factor for subsequent bleeding; 3, 14, 17, 19, 23, 24 our pooled hazard ratio for this risk factor was 3.73 (95% CI 1.26-11.1, p = 0.02). Annualized hemorrhage rates for unruptured CMs are generally consistent in the literature-ranging from 0.4% to 0.6% per patient-year across 3 studies. 2, 3, 23 On the other hand, those for ruptured CM vary widely, from 4.5% per patient-year to 22.9% per patient-year across numerous studies. [2] [3] [4] 14, 19, 23 This wide range is likely in part due to varying follow-up periods, as hemorrhage clustering has been consistently demonstrated 
in numerous studies, particularly within the first 2-3 years after an initial bleed. 3, 4, 14, 17 Indeed, 2 studies reporting the rehemorrhage rate within the 1st year reported relatively consistent rehemorrhage rates of 14% 4 and 18%.
14 Although 2 studies suggested female sex to be a significant risk factor for hemorrhage, 24, 29 another suggested male sex to be a significant risk factor.
14 Our pooled analysis demonstrated no significance of sex on the risk of CM hemorrhage. Although not formally statistically evaluated in our reviewed studies, multiple reports have not demonstrated pregnancy to be a significant risk factor for CM hemorrhage.
14,21,38 One of our reviewed studies noted that 12 patients with confirmed diagnoses of cerebral CMs subsequently had no symptoms during pregnancy.
14 In one study of 64 women harboring CMs during pregnancy, the annual hemorrhage rate during pregnancy was 3.4% per patient-year (2% per patient-year in the single CM group and 4% in the multiple CM group); the authors concluded that this did not substantially differ from the general population of patients with CMs. 21 In another study of 186 women harboring cerebral CMs, the annual hemorrhage rate during pregnancy was 1.15% per patient-year as compared with 1.01% during nonpregnant childbearing years (relative risk 1.13, 95% CI 0.34-3.75). 38 Two of 3 hemorrhages occurring during pregnancy resulted in mild permanent deficits in the mother; all 3 children were born healthy at term, 2 via cesarean section.
Although potentially confounded by a recent bleed increasing the apparent size of the lesion, size as an independent variable was not a significant risk factor for hemorrhage. Similarly, although we could not pool results for analyses of the impact of Zabramski grade 39 on hemorrhage risk, this factor, almost by definition, is confounded by hemorrhage (Table 5 ). Type I lesions, which were shown to have a greater risk of hemorrhage than others in 1 study, 19 are hemorrhagic by definition. We did not find lesion multiplicity to be a significant risk factor for hemorrhage. One study that found this factor to be significant evaluated hemorrhage risk on a per-patient rather than perlesion approach;
14 as such, the additive effect of harboring multiple lesions may have led to their result rather than an intrinsic proclivity of patients harboring multiple lesions to have a greater risk of hemorrhage from each CM. Radiographically apparent associated DVAs were not found to be a significant risk factor for hemorrhage; this may be in part due to the fact that all CMs may be associated with a venous component, often occult on standard MRI. 1, 10, 16, 18 In the often-cited surgical series of 300 brainstem CMs from the Barrow Neurological Institute, all were found in association with a venous component at surgery despite only seeing a venous anomaly in 28% of preoperative MRI studies. 1 Another study that evaluated 20 patients harboring 23 CMs on 7-T MR images found abnormal venous structures in all cases. 10 Prior reports have postulated this venous component to be crucial to CM development.
10,18
Studies with less stringent radiographic definitions of hemorrhage (including lesion size increases) reported greater rates of hemorrhage for deep CMs. 19, 31 This likely reflects the greater sensitivity of adjacent eloquent parenchyma to lesion morphological changes and smaller bleeds. Nevertheless, our pooled review did not demonstrate deep location to be a significant risk factor for hemorrhage overall. Indeed, it is difficult to provide a pathophysiological basis to explain a greater innate proclivity for deep CMs to hemorrhage as opposed to superficial lesions.
One of our reviewed studies reported a lower rate of hemorrhage among patients taking antiplatelet or antithrombotic medication. 36 In this study, no hemorrhages occurred over 82.4 patient-years of follow-up for 16 pa- tients receiving antiplatelet or antithrombotic therapy (p = 0.08 for comparison with 71 patients not receiving blood thinners). The authors suggested that the trend toward a lower rate of hemorrhage in patients on anticoagulants may be due to the alleviation of venous congestion. Eleven patients were receiving antiplatelet therapy (9 receiving aspirin, 2 receiving clopidogrel) and 5 were taking warfarin. In another study of 40 patients receiving antithrombotic therapy, the annual prospective hemorrhage rate was 0.41% per patient-year (one hemorrhage in a patient taking aspirin) over a total follow-up of 258 patient-years (median 6.5 years); 32 patients were receiving an antiplatelet agent: 6 were on anticoagulation, and 2 were on both.
15
In one study of 350 patients undergoing thrombolysis with recombinant tissue-type plasminogen activator for acute stroke, there was no significant difference in rates of symptomatic intracranial hemorrhage and parenchymal hemorrhage among patients harboring cerebral CMs as compared with those who did not.
13
None of our reviewed studies evaluated the impact of prior radiation on risk of CM hemorrhage. In one subgroup report of 32 patients with radiation-induced CMs, the median latency from radiation treatment to CM diagnosis was 12.0 years. 9 The risk of hemorrhage from radiation- induced CMs was 4.2% per person-year compared with 2.3% for nonradiation-induced CMs (p = 0.556). Hemorrhagic radiation-induced CM had relatively high rehemorrhage rates (11.0% per person-year vs 5.5%, p = 0.529).
Asymptomatic radiation-induced CMs also had a greater prospective risk of hemorrhage than asymptomatic nonradiation-induced CMs (4.2% vs 0.35%, p = 0.118).
9

Natural History of CMs
The natural history of an untreated cerebral CM must encompass not only the prospective risk of hemorrhage but also of seizures and focal deficits in addition to the psychological burden of harboring an untreated vascular malformation of the brain. The latter has not been well studied. As we illustrate, the risk of hemorrhage is approximately 2.5% per patient-year overall, influenced primarily by presentation modality (hemorrhagic vs nonhemorrhagic) as unruptured CMs have a relatively low prospective risk of hemorrhage (0.4%-0.6% per patient-year), 2, 3, 23 that increases substantially if the lesion bleeds. [2] [3] [4] 14, 19, 23 The prospective risk of a focal deficit independent of hemorrhage has been evaluated in 2 studies that described an overall clinical event rate for CMs: the sum of the hemorrhage and focal deficit (in the absence of hemorrhage) rates. In the study by Porter et al., the overall annual hemorrhage rate was 1.6%, increasing to 4.2% when including nonhemorrhagic events. 31 Thus, the annual rate of nonhemorrhagic neurological events in this study was 2.6%. The authors noted that these events occurred exclusively in deep lesions; the annual hemorrhage rate in this cohort was 4.1%, increasing to 10.6% per patient-year when including nonhemorrhagic events. Hemorrhage or a focal deficit at presentation and deep location were each significant risk factors for the occurrence of hemorrhage or a clinical event at follow-up. Importantly, there was no significant difference in the degree of recovery between hemorrhagic and nonhemorrhagic clinical events-approximately one-third of patients had resolution of symptoms, one-third improved, and one-third suffered permanent deficits. In another study that provided an aggregate rate of hemorrhage or focal deficits, the 5-year risk was 9.3% for patients presenting incidentally or with seizures, increasing to 42.4% for patients presenting with focal deficits or hemorrhage. 3 The prospective risk of seizures in patients with cerebral CMs has been evaluated in only a paucity of studies. 20, 28, 29 In one, the annual seizure risk was 2.4% per person-year, and the risk of recurrent seizures was 5.5% per patient-year.
29
In another more recent study, the 5-year risk of a first seizure was 6% in patients presenting with either intracranial hemorrhage or focal neurological deficits without seizures, decreasing to 4% for patients with incidentally discovered CMs. 20 However, the 5-year risk of developing epilepsy among patients presenting with a first-time seizure without hemorrhage or focal deficit was 94%. Another study of 107 patients with incidental cerebral CMs reported no new seizures over a median follow-up of 12.5 years (total of 1311 patient-years).
28
Limitations of This Study
This is a study of CM hemorrhage risk, a component of the entity's natural history. It is limited by the heterogeneity of incorporated reports and study designs. As mentioned, some studies recruited patients based on imaging review, while others included patients evaluated prior to anticipated treatment, introducing potential bias. All studies were limited by selection bias as patients may be selected out for early treatment. Although our overall hemorrhage rates were calculated across multiple studies, we were unable to accumulate adequate data from our reviewed studies to provide pooled hemorrhage rates for CM subclasses, such as unruptured versus ruptured CMs. Only 5 studies were incorporated in our pooled evaluation of hemorrhage risk factors. Selective outcome reporting of statistically significant results may have limited our analysis; however, all hemorrhage rates and hazard ratios provided in each study were incorporated in our analysis. We were unable to formally evaluate all potential risk factors such as pregnancy, prior radiation, and antithrombotic treatment. 
